{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:13:54Z","timestamp":1784614434466,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.msard.2023.104738","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T12:39:41Z","timestamp":1682685581000},"page":"104738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0691","authenticated-orcid":false,"given":"Autumn D.","family":"Zuckerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Simonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia L.","family":"Zagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wawrzyniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rightmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbi","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2023.104738_bib0001","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2023.104738_bib0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.msard.2023.104738_bib0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","article-title":"A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future","volume":"68","author":"Gholamzad","year":"2019","journal-title":"Inflamm. Res."},{"issue":"17","key":"10.1016\/j.msard.2023.104738_bib0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104738_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0006","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pds.4207","article-title":"Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations","volume":"26","author":"Evans","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2023.104738_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-022-00404-1","article-title":"Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study","author":"Araujo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"8","key":"10.1016\/j.msard.2023.104738_bib0008","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2023.104738_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PPA.S268829","article-title":"Disease progression in multiple sclerosis: a literature review exploring patient perspectives","volume":"15","author":"Celius","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0010","first-page":"2047","article-title":"Experiences of healthcare for people living with multiple sclerosis and their healthcare professionals","volume":"24","author":"Price","year":"2021","journal-title":"Health Expect. Int. J. Public Particip. Health Care Health Policy"},{"issue":"1","key":"10.1016\/j.msard.2023.104738_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36469\/jheor.2022.33288","article-title":"The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis","volume":"9","author":"Pardo","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"issue":"9","key":"10.1016\/j.msard.2023.104738_bib0012","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3111\/13696998.2015.1044276","article-title":"Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis","volume":"18","author":"Yermakov","year":"2015","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2023.104738_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104224","article-title":"Medication habits among persons with multiple sclerosis","volume":"68","author":"Neter","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104738_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103860","article-title":"A cross-sectional analysis of persistence to disease-modifying therapies in treatment na\u00efve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy","volume":"63","author":"Kozlicki","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Lahdenper\u00e4","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"19","key":"10.1016\/j.msard.2023.104738_bib0016","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/ajhp\/zxab277","article-title":"ASHP National Survey of health-system specialty pharmacy practice-2020","volume":"78","author":"Stubbings","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"11","key":"10.1016\/j.msard.2023.104738_bib0017","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2146\/ajhp150723","article-title":"Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems","volume":"73","author":"Habibi","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.msard.2023.104738_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/zxac212","article-title":"Health-system specialty pharmacy role and outcomes: a review of current literature","author":"Zuckerman","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.msard.2023.104738_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of Software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"issue":"2","key":"10.1016\/j.msard.2023.104738_bib0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap) - a metadata-driven Methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.msard.2023.104738_bib0022","series-title":"A language and Environment for Statistical Computing","year":"2022"},{"key":"10.1016\/j.msard.2023.104738_bib0023","article-title":"Adherence to Disease-Modifying Therapies At A Multiple Sclerosis Clinic: The Role Of The Specialty Pharmacist","author":"Banks","year":"2019","journal-title":"J. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0018","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2146\/ajhp130495","article-title":"Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis","volume":"71","author":"Hanson","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2146\/ajhp130495","article-title":"Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis","volume":"71","author":"Hanson","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"9","key":"10.1016\/j.msard.2023.104738_bib0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12325-011-0054-9","article-title":"Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis","volume":"28","author":"Halpern","year":"2011","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.msard.2023.104738_bib0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7224\/1537-2073.2011-038","article-title":"Facilitating medication adherence in patients with multiple sclerosis","volume":"15","author":"Remington","year":"2013","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2023.104738_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/zxaa135","article-title":"Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies","author":"McCabe","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"10","key":"10.1016\/j.msard.2023.104738_bib0028","first-page":"1438","article-title":"Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies","volume":"27","author":"Academia","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"2","key":"10.1016\/j.msard.2023.104738_bib0029","first-page":"95","article-title":"The effect of an integrated health system specialty pharmacy on HIV antiretroviral therapy adherence, viral suppression, and CD4 count in an outpatient infectious disease clinic","volume":"26","author":"Barnes","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"4","key":"10.1016\/j.msard.2023.104738_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1060028016683495","article-title":"Evaluation of a Hepatitis C patient management program at a University Specialty Pharmacy","volume":"51","author":"Zaepfel","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.msard.2023.104738_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19042203","article-title":"Adherence to therapy in patients with multiple sclerosis-review","volume":"19","author":"Ko\u0142tuniuk","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.msard.2023.104738_bib0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1186\/s12913-021-07012-z","article-title":"Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study","volume":"21","author":"Sippel","year":"2021","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.msard.2023.104738_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102016","article-title":"Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: a qualitative analysis","volume":"41","author":"Stratos","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2023.104738_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113177","article-title":"Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects","volume":"10","author":"Fischer","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.msard.2023.104738_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102856","article-title":"Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study","volume":"50","author":"Zhang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2023.104738_bib0036","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1352458516657440","article-title":"Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study","volume":"23","author":"McKay","year":"2017","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2023.104738_bib0037","first-page":"732","article-title":"Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system","volume":"27","author":"Brouwer","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2023.104738_bib0038","article-title":"Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease","author":"Kozlicki","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"10.1016\/j.msard.2023.104738_bib0039","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","volume":"27","author":"Engmann","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"9","key":"10.1016\/j.msard.2023.104738_bib0040","first-page":"1273","article-title":"Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression","volume":"27","author":"Mardan","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"10.1016\/j.msard.2023.104738_bib0041","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1331\/1544345054003804","article-title":"Factors leading patients to discontinue multiple sclerosis therapies","volume":"45","author":"Daugherty","year":"2005","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"10.1016\/j.msard.2023.104738_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.647811","article-title":"Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network","volume":"12","author":"Hillert","year":"2021","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104738_bib0043","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1037\/a0036322","article-title":"Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis","volume":"59","author":"Turner","year":"2014","journal-title":"Rehabil. Psychol."},{"issue":"4","key":"10.1016\/j.msard.2023.104738_bib0044","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"Treadaway","year":"2009","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104738_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/pharmacy7040163","article-title":"An integrated health-system specialty pharmacy model for coordinating transitions of care: specialty medication challenges and specialty pharmacist opportunities","volume":"7","author":"Zuckerman","year":"2019","journal-title":"Pharmacy"},{"issue":"3","key":"10.1016\/j.msard.2023.104738_bib0046","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:41Z","timestamp":1761901841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"alternative-id":["S2211034823002420"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104738","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104738"}}